Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.
Umscheid CA, Maguire MG, Pines JM, Everett WW, Baren JM, Townsend RR, Mines D, Szyld D, Gross R. Untreated hypertension and the emergency department: a chance to intervene? Acad Emerg Med. 2008 Jun;15(6):529-36. doi: 10.1111/j.1553-2712.2008.00132.x
Umscheid CA, Maguire MG, Pines JM, Everett WW, Baren JM, Townsend RR, Mines D, Szyld D, Gross R. The prevalence of and risk factors associated with untreated hypertension in ED patients. Poster presented at the 2007 Society for Academic Emergency Medicine Conference; May 2007. Chicago, IL. [abstract] Acad Emerg Med. 2007; 14(5 Suppl 1):S117.